Mizuho Reiterates “$65.00” Price Target for Zogenix (NASDAQ:ZGNX)

Mizuho set a $65.00 target price on Zogenix (NASDAQ:ZGNX) in a report issued on Monday, TipRanks reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus set a $71.00 price target on shares of Zogenix and gave the stock a buy rating in a research report on Wednesday, August 7th. Needham & Company LLC initiated coverage on shares of Zogenix in a research report on Monday. They set a buy rating and a $58.00 price target for the company. BidaskClub lowered shares of Zogenix from a buy rating to a hold rating in a research report on Tuesday, September 10th. Piper Jaffray Companies set a $64.00 price objective on shares of Zogenix and gave the stock a buy rating in a research report on Monday, August 26th. Finally, JMP Securities set a $69.00 price objective on shares of Zogenix and gave the stock a buy rating in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $58.45.

ZGNX stock traded up $1.09 on Monday, hitting $44.58. 277,600 shares of the company were exchanged, compared to its average volume of 574,935. Zogenix has a twelve month low of $33.43 and a twelve month high of $56.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.19 and a quick ratio of 7.19. The business’s fifty day moving average is $41.70 and its two-hundred day moving average is $42.81. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -13.80 and a beta of 1.94.

Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.06). The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $15.00 million. During the same period last year, the business earned ($0.83) earnings per share. Equities research analysts expect that Zogenix will post -3.81 earnings per share for the current year.

In other news, EVP Gail M. Farfel sold 3,446 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $52.00, for a total value of $179,192.00. Following the completion of the transaction, the executive vice president now directly owns 4,891 shares in the company, valued at $254,332. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael P. Smith sold 15,000 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $50.00, for a total transaction of $750,000.00. Following the completion of the transaction, the chief financial officer now owns 16,387 shares of the company’s stock, valued at $819,350. The disclosure for this sale can be found here. Insiders sold 24,696 shares of company stock valued at $1,241,692 in the last three months. Company insiders own 4.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Zogenix in the 1st quarter worth about $193,000. First Midwest Bank Trust Division acquired a new position in Zogenix during the 2nd quarter valued at about $346,000. SG Americas Securities LLC increased its stake in Zogenix by 113.6% during the 2nd quarter. SG Americas Securities LLC now owns 14,226 shares of the company’s stock valued at $680,000 after buying an additional 7,566 shares during the period. First Trust Advisors LP acquired a new position in Zogenix during the 2nd quarter valued at about $1,870,000. Finally, Aperio Group LLC increased its stake in Zogenix by 14.9% during the 2nd quarter. Aperio Group LLC now owns 5,875 shares of the company’s stock valued at $281,000 after buying an additional 762 shares during the period.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

See Also: What are momentum indicators and what do they show?

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.